When Pfizer completed its acquisition of Metsera in November 2025, it wasn't buying an approved drug — it was buying a pipeline. The deal, structured as $65.60 per share in cash plus a contingent value right worth up to another $20.65 per share tied to future milestones, gave Pfizer control of a small obesity-focused biotech whose two lead candidates, MET-097i and MET-233i, are still investigational and have not been evaluated or approved by the FDA for any use. Here's what each one is and how far along the research actually is.
MET-097i: A Long-Acting GLP-1 Receptor Agonist
MET-097i is an injectable GLP-1 receptor agonist designed to work like semaglutide or liraglutide — activating the same gut-hormone receptor that slows stomach emptying and signals fullness to the brain — but engineered for a longer duration of action, with the goal of supporting less-frequent dosing than once-weekly injectables.
The most detailed public data come from a Phase 2b study (internally named Vesper-1) that Metsera reported in September 2025. In that trial, patients with overweight or obesity who received the highest tested dose lost a mean of 14.1% of body weight, after accounting for the placebo group's own weight change, over 28 weeks. An exploratory look at 36-week data suggested the weight loss curve hadn't leveled off yet, though that finding is preliminary. On the safety side, the company reported that only 2 of 239 trial participants stopped the drug because of side effects — a notably low discontinuation rate that the company and some outside coverage framed as a tolerability advantage, though cross-trial comparisons like this should be read cautiously since they weren't run head-to-head against another drug in the same study.
A separate, smaller Phase 2b study (Vesper-3) tested less-frequent, monthly-style dosing options. Early interim data described a modest increase in gastrointestinal side effects such as nausea, vomiting, and diarrhea relative to placebo, consistent with the GI side-effect profile seen across this entire drug class.
MET-233i: An Amylin Analog, Still in Phase 1
MET-233i is described in Metsera's and Pfizer's public materials as a monthly injectable amylin analog — a different hormone target than GLP-1, more similar in mechanism to cagrilintide or eloralintide. Amylin is a pancreatic hormone that, like GLP-1, affects satiety and gastric emptying, and pairing an amylin analog with a GLP-1 drug is a strategy several companies are pursuing to try to improve weight loss or reduce muscle loss relative to a GLP-1 drug alone. As of Pfizer's acquisition announcement, MET-233i was in Phase 1 testing, both as a standalone candidate and in combination with MET-097i. Public, detailed efficacy data from that Phase 1 program have not been released in the same depth as the MET-097i Phase 2b results.
What the Acquisition Does and Doesn't Mean
An acquisition is a business transaction, not a regulatory milestone. Pfizer's purchase of Metsera reflects the company's bet that this pipeline is worth developing further, following Pfizer's own earlier struggles to advance an internal oral GLP-1 candidate. It does not mean MET-097i or MET-233i have been proven safe or effective in the kind of large, longer-duration Phase 3 trials the FDA requires before approval, and it does not mean either drug is available, or will become available, on any particular timeline. At the time of the deal, MET-097i was described as approaching Phase 3, which is typically a multi-year stage of development on its own.
Where This Fits in the Broader GLP-1 Landscape
MET-097i and MET-233i join a crowded field of next-generation obesity candidates — alongside retatrutide, amycretin, survodutide, and others covered elsewhere on this site — all competing on some combination of efficacy, tolerability, and dosing convenience. Pfizer's stated rationale for the deal centered on MET-097i's early tolerability signal and its potential fit alongside an amylin-pathway combination, but outside analysts have also noted that cross-trial comparisons this early in development often don't hold up once larger, controlled studies are run.
For now, both candidates remain unapproved investigational drugs. Anyone following obesity-drug news should treat early-phase percentages, including the ones in this article, as a first look rather than a final verdict, and should talk to a licensed physician about any current, FDA-approved option rather than an investigational pipeline asset still years from a possible approval decision.